Previous 10 | Next 10 |
Epizyme (EPZM): Q3 GAAP EPS of -$0.55 beats by $0.06.Revenue of $3.57M (-37.6% Y/Y) misses by $2.32M.Press Release For further details see: Epizyme EPS beats by $0.06, misses on revenue
Company Reports 55% Growth in Net Revenue of TAZVERIK ® Compared with 2Q 2020 Expansion of Loan Facility with Pharmakon Advisors; $150 Million Drawn Down to Fund Important Growth Initiatives and Extend Operating Runway into At Least 2023 On-Track to Initiate E...
Additional Capital Expected to Extend Company’s Operating Runway into At Least 2023 Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the company has ...
Epizyme (NASDAQ:EPZM) is scheduled to announce Q3 earnings results on Friday, November 6th, before market open.The consensus EPS Estimate is -$0.60 (-50.0% Y/Y) and the consensus Revenue Estimate is $5.89M (+3.0% Y/Y).Over the last 1 year, EPZM has beaten EPS estimates 100% of the time and ha...
[[AES]], [[AMRX]], [[COTY]], [[CQP]], [[CVS]], [[CWT]], [[DISH]], [[DOC]], [[ELAN]], [[ENB]], [[EPZM]], [[ESNT]], [[GCP]], [[GOLF]], [[HMSY]], [[HRC]], [[HSY]], [[LNG]], [[MAR]], [[MBUU]], [[MD]], [[MGA]], [[MOG.A]], [[MYL]], [[PRIM]], [[SABR]], [[SSP]], [[TILE]], [[TU]], [[UFS]], [[VIAC]], [...
Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its third quarter 2020 financial results and other busine...
Data Supported Accelerated Approvals of TAZVERIK for the Treatment of Both Epithelioid Sarcoma and Relapsed/Refractory Follicular Lymphoma Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic ...
Epizyme, Inc . (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in a fireside chat during the Morgan Stanley 18th ...
Image source: The Motley Fool. Epizyme Inc (NASDAQ: EPZM) Q2 2020 Earnings Call Aug 4, 2020 , 8:30 a.m. ET Operator Continue reading
Epizyme, Inc. (EPZM) Q2 2020 Earnings Conference Call August 4, 2020, 8:30 am ET Company Participants Alicia Davis - IR, THRUST Strategic Communications Rob Bazemore - President & CEO Matt Ros - Chief Strategy & Business Officer Paolo Tombesi - CFO Shefali Agarwal - C...
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...